Similar content being viewed by others
References
Grundy SM et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239
Superko HR (1996) Beyond LDL cholesterol reduction. Circulation 94: 2351–2354
Fredrickson DS et al. (1967) Fat transport in lipoproteins—an integrated approach to mechanisms and disorders. N Engl J Med 276: 148–156
Cromwell WC and Otvos JD (2004) Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6: 381–387
Kathiresan S et al. (2006) Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113: 20–29
Sniderman AD et al. (2003) Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 91: 1173–1177
Blake GJ et al. (2002) Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106: 1930–1937
Olsson A et al. (2006) Apolipoprotein B/A1 ratio is a better discriminator of risk of coronary heart disease than is LDL/HDL cholesterol ratio in the IDEAL study [abstract #Tu-W20:4]. Atheroscler 7 (Suppl): 161
Sattar N et al. (2004) Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 110: 2687–2693
Barter PJ et al. (2006) Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy; report of the thirty-person/ten-country panel. J Intern Med 259: 247–258
Acknowledgements
JH Stein is funded by the National Center for Research Resources (RR-1617601).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JH Stein has served as a consultant for Abbott, LipoScience, Pfizer, and Sanofi-Aventis. He has received research and/or training grants from Astra-Zeneca, Bristol-Myers Squibb, Kos, LipoScience, and Sanofi-Aventis. He has been on the Speaker's Bureaus for Kos, LipoScience, Merck, Pfizer, Sanofi-Aventis, Schering-Plough, and Takeda. PE McBride has served as a consultant for Merck. He has been on the Speaker's Bureaus for Abbott, Bristol-Myers Squibb, Kos, Merck, Pfizer, Reliant, Sankyo-Pharma, and Schering-Plough.
Rights and permissions
About this article
Cite this article
Stein, J., McBride, P. Should advanced lipoprotein testing be used in clinical practice?. Nat Rev Cardiol 3, 640–641 (2006). https://doi.org/10.1038/ncpcardio0719
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0719
- Springer Nature Limited